The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
TG Therapeutics stock surged after H.C. Wainwright raised its price target to $70, indicating a potential upside of 76.1%. On the same day, the company reported Q1 2026 revenues of approximately $205 million, driven by BRIUMVI sales. TG Therapeutics also raised its full-year global revenue target to approximately $925 million.